Asset Management One Co. Ltd. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Asset Management One Co. Ltd. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,338 shares of the biopharmaceutical company's stock after buying an additional 2,358 shares during the period. Asset Management One Co. Ltd. owned about 0.06% of Regeneron Pharmaceuticals worth $39,537,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $1.98 during midday trading on Wednesday, reaching $520.29. 639,396 shares of the stock traded hands, compared to its average volume of 891,374. The stock has a market capitalization of $56.17 billion, a PE ratio of 13.25, a P/E/G ratio of 1.87 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The company's 50 day moving average is $556.44 and its 200 day moving average is $637.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research note on Monday, June 2nd. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research note on Friday, May 30th. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.